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ARTICLE IN PRESS

Conversational Vocal Intensity in Parkinson’s Disease:
Treatment and Environmental Comparisons
*Ramya Konnai, †Meredith Van Harn, and ‡Alice Silbergleit, *zWest Bloomﬁeld, and yDetroit, Michigan
Abstract: Background. Vibrotactile Feedback (VF) using wearable devices is an emerging treatment option
for hypophonia in Individuals with Parkinson’s disease (IwPD). Studies evaluating the effectiveness of VF in
improving conversational vocal intensity in real-life environment in IwPD are limited.
Objective. To determine the effect of VF on conversational vocal intensity and compare vocal intensity between
a) clinic and real-life environment b) VF and Lee Silverman Voice Treatment (LSVT LOUDÒ )vs. VF alone in
IwPD using a portable voice monitor (VocaLog2).
Methods. Eight individuals with hypophonia secondary to PD were randomly assigned to two treatment
groups- VF and LSVT LOUDÒ (Group 1) and VF (Group 2). VF was provided using VocaLog2 device. Duration of treatment was 4 weeks for both groups. Vocal intensity was measured in the real-life environment at baseline, during treatment, and at one-month follow-up.
Vocal intensity in clinic was obtained at baseline and one-month follow-up. Voice Handicap Index (VHI) questionnaire was administered at baseline and one-month follow-up.
Results. There was no signiﬁcant difference in conversational vocal intensity between a) clinic and real-life environment at any point of time b) baseline and follow up for both treatment groups c) the two treatment groups at
baseline, during each of the 4 weeks of treatment and at follow up d) VHI baseline and one month follow up
scores.
Conclusion. VF, including when combined with LSVT LOUDÒ , is limited in improving conversational vocal
intensity in real-life in IwPD. The effects of frequency and duration of VF on conversational vocal intensity must
be systematically investigated using large scale studies in IwPD.
Key words: Vocal intensity—Parkinson's disease—Wearable device—Vibrotactile feedback—Hypophonia—
LSVT LOUDÒ —Real-life environment.

INTRODUCTION
Parkinson’s disease (PD) is estimated to affect over one million people across North America by 2030.1 Speech is
affected in about 90% of Individuals with Parkinson’s Disease (IwPD) during the disease course.2 Speech deﬁcits in
PD are associated with an altered recruitment of the main
motor cerebral regions (orofacial motor cortex, cerebellum),
and an increased involvement of premotor and prefrontal
cortices.3,4 Hypokinetic dysarthria is a collective name for
speech impairments in PD and is characterized by decreased
vocal loudness, monotony of pitch, breathy, and harsh voice
quality, reduced stress, variable rate, short rushes of speech,
and imprecise consonants.5 Decreased vocal intensity or
hypophonia can be an initial speech symptom in PD.6
Hypophonia is attributed partly to hypokinesia (reduced
amplitude of movement) and rigidity caused by underlying
dopaminergic deﬁciency.7-12 Abnormalities in central sensory processing (reduced awareness of soft voice), internal
cueing (difﬁculty self-generating increased loudness), and
self-monitoring of speech output also contribute to
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hypophonia.13-22 Both problems of sensory processing and
internal cueing, in addition to the motor problems, may
contribute to challenges in treatment.23 Studies have compared the conversational vocal intensity of IwPD with
healthy controls using portable voice monitors and reported
2-8 dB decrease in the PD group.24,25 Hypophonia contributes to signiﬁcant difﬁculty communicating and participating effectively in a variety of daily speaking situations.
Voice and speech assessments are traditionally obtained
in a controlled environment such as soundproof booths in a
lab or clinic setting to ensure data reliability and replicability. Voice and speech produced in a lab setting may not necessarily represent how IwPD use their voice in their daily
speaking situations such as in a restaurant, at work, or in
the car. While “lab speech” is necessary to research certain
aspects of speech which requires systematic experimental
control (eg, vowel acoustics or aerodynamics), it is important to focus on functional tasks such as conversation in
real-life environments when studying carry over of treatment effects. The absence of real-life environmental
demands such as cognitive load, performance effects, background noise, and environmental cues in the clinic may produce results different than that of real-life environment.26
Studies comparing voice use in clinic and real-life environments in IwPD are limited and the results are mixed.25-27
The differences in the ﬁndings of these studies is likely due
to differences in methodology such as the number of participants studied, length of conversation samples, and technology used to monitor vocal intensity. More studies are
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needed to investigate if IwPD use their voice differently in
reallife environment compared to the clinic as real-life communication is important to their quality of life. Portable
voice monitors are becoming available to monitor voice in
real-life. One such monitor that is available for research is
the Vocalog2 (VL2, Grifﬁn Laboratories, Temecula, CA).
The VL2 monitors vocal intensity and can provide vibrotactile feedback when an individual speaks above or below a
threshold level. It does not measure fundamental frequency
or environmental noise. The accuracy of VL2 in its measurement of vocal intensity was determined in reference to a
head mounted microphone and there was good agreement
with a mean error of -0.4 dB.28 It should be noted that the
beta version of VocaLog (software version 1.2.4.2) was
tested in 3 different studies but the device has been modiﬁed
since then.29-31 The VL2 is different from the beta version in
terms of the sensor used and calibration process (C. Grifﬁn,
personal communication, Nov 5, 2020). A recent study
monitored IwPD in their real-life environment using a portable voice accumulator and found that IwPD use their
voice 50%-60% less than their matched healthy controls in
daily life.25 Maintaining vocal volume in a patient’s everyday life is crucial for continuing socialization and limiting
communication isolation and the potential accompanying
depression found in IwPD.32
Traditionally, voice therapy for hypophonia is based
either on behavioral treatment which involves training to
strengthen muscles involved with coordination of respiration, phonation, and articulation or using devices that
provide environmental cues or biofeedback or voice
ampliﬁcation.33 Lee Silverman Voice Treatment, LSVT
LOUDÒ (LSVT Global, Tucson, AZ) is a standardized
and leading treatment of choice for hypophonia in
IwPD.34 This technique includes an intensive, high effort
treatment with focus on increasing phonatory effort and
vocal fold adduction as well as improving sensory perception of effort.22 Treatment is delivered 4 times a week
over 4 weeks. Therapy tasks include a hierarchy of loud
sustained vowel to functional phrases, reading, and conversational speech.22 Existing randomized control studies
have shown that LSVT LOUDÒ can result in improved
vocal intensity in monologue from 4.7 to 5.5 dB SPL
and that the beneﬁts of treatment can last for up to
2 years.22,35-37 Recalibration of internal cueing and selfregulation of vocal effort is a mainstay of LSVT
LOUDÒ .35 However, reports regarding the carry-over of
LSVT LOUDÒ treatment to real-life conversation are
lacking with the exception of a single subject study
where the IwPD increased voice intensity with 4.1 dB in
real-life and 5.6 dB in the lab post-treatment.38
Wearable devices may help with carryover of treatment
effects for some IwPD or be an alternate option to treat
hypophonia. The use of wearable devices for treatment of
hypophonia in IwPD dates to the 1980.39,40 Some devices
use biofeedback to improve hypophonia. Biofeedback is a
“process of transducing some physiologic variable, transforming the signal to extract useful information and

displaying that information to the subject in a format that
will facilitate learning to regulate the physiological variable.”41 Biofeedback can be auditory, visual or vibrotactile
in nature. Recently, VF was provided to a small group of
six IwPD using Voxlog, a portable voice monitor and a
1.5 dB increase in conversational vocal intensity was demonstrated compared to no feedback condition and vocal
intensity did not decrease signiﬁcantly when feedback was
removed.23 Van Stan et al, (2015) point out that 1.5 dB may
be statistically signiﬁcant but may not represent a clinically
signiﬁcant change considering that IwPD speak approximately 10 dB lower than age matched controls.42 In a single
case study using the Ambulatory Phonation Monitor
(APM), a portable voice monitor, conversational vocal
intensity decreased by 9 dB post-biofeedback when measured in the clinic.43 Improvements in vocal intensity and
generalization of treatment beneﬁts could be related to the
frequency, duration, type of biofeedback provided. A comparison of six different biofeedback conﬁgurations in IwPD
showed that activating feedback when an individual speaks
3 dB below their mean vocal intensity study for at last
500 ms elicited optimal outcomes.44 Also, intermittent biofeedback has been shown to be more effective than constant
feedback.45 Hence most studies in the literature investigating the effect of biofeedback on vocal intensity have used
intermittent feedback but the nature of intermittent feedback varies within studies.23,46 In summary, VF by itself
seems to be limited in improving vocal intensity in IwPD.
Thus, a combination of treatments such as LSVT LOUDÒ
and VF may be beneﬁcial in improving vocal intensity in
natural environments in IwPD compared to VF alone. This
preliminary exploratory study aimed to address this using
the VL2. Evidence also suggests that IwPD seem to need
more time to achieve motor learning, especially to achieve
automatization.47 The previous studies that utilized VF in
IwPD were limited to one week and this may not have been
enough to improve vocal intensity in IwPD.23,43 Another
rationale for undertaking this study was to provide VF for a
longer duration (2 weeks) to facilitate motor learning . The
aims and hypotheses of the present study are
1. To determine the effects of VF on conversational vocal
intensity in IwPD in real-life environments and compare it
with VF and LSVT LOUDÒ treatment combination.
We hypothesized that VF will produce higher vocal intensity at the end of treatment compared to baseline and conversational vocal intensity using LSVT LOUDÒ and VF
treatments will be greater than using VF alone.
2. To compare conversational vocal intensity obtained in
the clinic vs. real-life environments in IwPD using VL2
monitor.
We hypothesized that conversational vocal intensity in
the clinic will be greater than the real-life environment.
3. To assess short-term carry over of LSVT LOUDÒ and
VF treatments in real life environment.
We hypothesized that both treatment groups (VF combined LSVT LOUDÒ and VF) will carry over to real-life
after a one-month time period.
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METHODS
Participants
Twelve individuals (6 males) were initially enrolled in the
study. They were recruited from an outpatient clinic in a
hospital setting. Inclusion criteria included diagnosis of
idiopathic PD by a neurologist specializing in movement
disorders, complaints of hypophonia, and normal hearing
based on audiological evaluation within the past year of
enrollment. Exclusion criteria included DBS surgery,
dementia as reported by the physician in the patient’s
medical record, LSVT LOUDÒ therapy in the last two
years, and vocal fold pathology unrelated to hypokinetic
dysarthria (such as vocal fold nodules). Study participants
retained their regular medication schedule. Four IwPD
dropped out of the study due to personal reasons. Therefore, eight IwPD completed the study, Table 1. The study
was approved by the institutional review board at Henry
Ford Health System. All participants signed an informed
consent form.

Instrumentation
The VocaLog2 (VL2) system was used to measure participants’ vocal intensity in the clinic and in real-life environments. The VL2 system consists of the VocaLog 2 activity
monitor worn by the subject to monitor and record vocal
activity, the computer software, and a calibrated Microphone (Samson Go mic model SAGOMIC). Using the
VocaLog2 Desktop Application on a computer, the clinician downloaded the data recorded by the monitor. The
VL2 monitor consists of a laryngeal sensor and a neck band
and logs sound pressure level using the dBC scale. It was
also used to provide VF when vocal intensity dropped below
a pre-determined threshold for 500 ms. This feature can be
disabled by turning a switch when VF is not required. Subjects were sized for either of the available sizes, VL2 28 or
VL2 35, to ensure full contact of the laryngeal sensor with
the neck.

Procedure
An initial speech evaluation was completed in the clinic
consisting of case history, Consensus Auditory-Perceptual
Evaluation of Voice (CAPE-V)48 to determine the severity
of hypophonia, Voice Handicap Index (VHI)49, a patient
reported outcomes measure that quantiﬁes the impact of a
voice disorder on a person’s quality of life, the St. Louis
University Mental Status (SLUMS) examination50, and
videostroboscopy by a speech-language pathologist (AS,
third author). The videostroboscopy recordings were further reviewed by a laryngologist to rule out vocal fold
pathology unrelated to hypokinetic dysarthria in all participants. Patients that were eligible and consented to participate in the research study returned to the clinic for a
second visit to calibrate the VL2 and measure baseline conversational vocal intensity. Baseline vocal intensity was
obtained in the clinic using the VL2 during 20-minutes of
informal conversation with the clinician. For the purpose
of this study, “conversational vocal intensity” was deﬁned
as vocal intensity measured during an unstructured dialogue between IwPD and clinician/communication partner
(s). Conversation revolved around the participants’ topics
of interest. Following this clinic visit, baseline vocal intensity was also measured in the real-life environment. Reallife environment was deﬁned as the natural environment
where an individual is likely to communicate such as
home, ofﬁce, restaurant, etc. Participants wore the VL2
monitor for a total of four hours each day for three days
for baseline measurement of vocal intensity in real-life.
Participants were instructed to wear the VL2 monitor
when they were likely to participate in conversation (eg,
phone conversations, social outings). Participants were
also instructed to maintain a daily log of when the device
was turned on and off, type of speaking situation (home,
restaurant, work, etc), number of people present, comments. The purpose of this daily log was to verify the date
and time data that was displayed on the VL2 with the times
entered by the participant. Following baseline

TABLE 1.
Subject Characteristics
Subject

1
2
3
4
5
6
7
8

Age

Gender

Yearsof
PD

51
58
71
63
61
76
56
74

M
M
M
F
F
M
M
M

8
10
1
7
1
5
4
6

Severityof dysphonia
(based on CAPE-V
loudness scale)
Mild
Moderate
Mild-moderate
Mild
Mild
Mild
Moderate
Moderate

CAPE-V
loudness
score
14
46
27
15
18
10
30
13

VHI score
&Severity

Treatment
Group

Cognition

60 (severe)
70 (severe)
9 (normal)
65 (severe)
43 (moderate)
52 (moderate)
90 (severe)
58 (severe)

VF only
VF only
VF only
VF only
VF only
LSVT & VF
LSVT & VF
LSVT & VF

Normal
Normal
Normal
Normal
Normal
MCI
MCI
MCI

Abbreviation: CAPE-V, Consensus Auditory-Perceptual Evaluation of Voice; VHI, Voice Handicap Index; VF, Vibrotactile Feedback; LSVT, Lee Silverman Voice
Treatment LOUDÒ ; MCI, Mild Cognitive Impairment
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measurements, participants were then randomly assigned to
one of two treatment groups- Group 1 received VF via the
VL2 (outside the clinic) and LSVT LOUDÒ (in-clinic) while
Group 2 received VF only (outside the clinic). Group 1
consisted of ﬁve participants with normal cognition and
group 2 had three participants with mild cognitive
impairment (MCI) who lived independently and were able
to follow directions. Group 1 received LSVT LOUDÒ
treatment by a certiﬁed LSVT LOUDÒ trained clinician
(RK, ﬁrst author) according to the recommended protocol
of 4 days per week for 4 weeks. Participants in Group 1
did not wear the VL2 during LSVT LOUDÒ therapy in the
clinic but wore the monitor outside of the clinic to monitor
their vocal intensity in real-life. Data from the VL2 was
downloaded for Group 1 once a week. Participants in
group 2 returned to clinic at the end of each week for four
weeks to download the data from the VL2. Informal discussion took place with the clinician during data download
for both groups where the clinician reminded them to check
for placement of the VL2 sensor, to pay attention to the
VF, and made sure that the daily log was being maintained.
Both groups wore the VL2 outside of the clinic for 4 weeks
during treatment, but VF was provided intermittently during weeks one and three for both groups. The VF feature
was turned off by the clinician in the clinic for weeks two
and four. During weeks one and three, VF was automatically initiated by the VL2 when participants spoke below
the set threshold level for 500ms. The threshold level was
set to 4 dB above the participant’s average baseline vocal
intensity obtained in the real-life environment. Participants
were aware whether VF was on or off. Participants were
instructed that the VF was a cue that their volume was
dropping and that they had to speak louder when they felt
the vibration. They were speciﬁcally instructed not to
ignore the VF. At the end of 4 weeks of treatment, participants returned the VL2 monitor to the clinic. All participants returned to the clinic one month after the end of
treatment for follow-up. Vocal intensity during conversation was monitored for 20 minutes in the clinic during the
one-month follow-up session using the VL2 system. The
VHI questionnaire was re-administered in the clinic during
this follow-up visit. Participants were sent home with the
VL2 to be worn for three days (four hours each day) to
measure vocal intensity outside the clinic. They did not
receive any VF during these three days and the goal was to
monitor their vocal intensity to assess for short-term carry
over. Participants returned to the clinic following the 3days to return the VL2 monitor and downloading of the
data. During this visit, participants provided feedback on
the VL2 on various aspects such as comfort, nature of
vibration. Figure 1 shows a ﬂowchart of the data collection
process. All analyses were performed using SAS 9.4 (SAS
Institute Inc, Cary, NC, USA). A repeated-measures generalized estimating equations approach was used to account
for the lack of independence inherent in this design. Data
are presented using least-squared means and standard
errors. Statistical signiﬁcance was set at P < 0.05.

RESULTS
There was no signiﬁcant difference in conversational vocal
intensity between a) clinic and real-life environment at any
point of time (P = 0.268, Table 2) b) the two groups at baseline, during each of the 4 weeks of treatment and at follow
up (Table 3). However, when data was pooled across the
four weeks, group two had signiﬁcantly higher conversational vocal intensity than group 1 (P = 0.044) c) VF on and
off in group 2 (P = 0.678) d) baseline and one-month follow-up for both treatment groups in real life environment
and in the clinic (Table 4) e) VHI baseline and one month
follow up scores (P = 0.082). Figure 2 shows the average
vocal intensity for each participant at various time points.
Only participant eight with moderate hypophonia at baseline showed increase in vocal intensity post-treatment
(LSVT LOUD & VF) compared to baseline. No improvement was noted in conversational vocal intensity between
baseline and follow up for remaining seven participants.
DISCUSSION
Clinic vs. real-life environment comparison: In this study the
average vocal intensity obtained in the clinic was approximately 2 dB higher than that obtained in the real-life environment, but this difference was not statistically signiﬁcant.
One of the reasons for this ﬁnding is possibly the duration
of conversation sample obtained in the clinic (20 minutes).
Previous studies comparing clinic and home environments
have obtained monologue or connected speech samples in
the clinic that are of shorter duration (30 seconds-three
minutes).23,26,27,38 Twenty minutes of conversation in clinic
was obtained in this study to be consistent with the LSVT
LOUDÒ protocol.37 A preliminary investigation into establishing initial benchmarks for obtaining robust estimates of
long-term monitoring of voice recommended an hour-long
monitoring of voice for an error rate of about 5% in the
average sound pressure level curve.51 An hour-long monitoring of vocal intensity may not be feasible in a busy clinic
environment. Accuracy level of the SPL measures obtained
during a 20-minute sample may have an increased error rate
more than 5% but is a practical time frame for clinical voice
assessment. It is also possible that when recordings last for
20 minutes in the clinic, that “performance effect” or Hawthorne effect (deﬁned as alteration of a subject’s behavior
due to their awareness of being observed)52 is less likely
compared to the 30 second to 3 minutes of monologue samples. The correlation between recording duration in the
clinic and conversational vocal intensity must be further
investigated in IwPD. Since there was no difference in vocal
intensity with 20 minutes of connected speech data obtained
in the clinic and real-life environment, this duration may be
recommended for clinical assessment for a good representation of conversational vocal intensity in the real-life environment.
Effects of treatment on conversational vocal intensity in
real-life environments: This study’s ﬁndings are in agreement
with another similar study where the combined use of LSVT
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General experimental protocol

Baseline measurement of vocal
intensity using VL2
Pre-experimental protocol
-

-Clinic (20 min monitoring)

CAPE-V
VHI
SLUMS
Videostroboscopy

Week 1
Group 1
-4 days of VF in
real-life and
LSVT LOUD in
clinic with data
download on
session 4
Group 2
- 4 days of VF
- Return to clinic
for data download

- Real-life (3 days; 4 hours each
day)
Treatment

Week 2
Group 1
-4 days of VL2
without VF in reallife and LSVT
LOUD in clinic
with data download
on session 8
Group 2
--4 days of VL2
without VF
- Return to clinic for
data download

Week 3
Group 1
-4 days of VF in
real-life and LSVT
LOUD in clinic
with data download
on session 12
Group 2
- 4 days of VF
- Return to clinic
for data download

Week 4
Group 1
-4 days of VL2
without VF in reallife and LSVT
LOUD in clinic
with data
download on
session 16
Group 2
--4 days of VL2
without VF
- Return to clinic
for data download

1-month Follow-up
Measurement of vocal intensity using
VL2 (no VF treatment)
-Clinic (20 min monitoring) with VHI
-Real-life (3 days; 4 hours each day)
- Drop off VL2 in clinic for data
download and completed VL2-feedback
questionnaire

FIGURE 1. Flowchart of data collection process
LOUDÒ and VF in IwPD did not demonstrate better maintenance of target loudness levels than LSVT LOUDÒ
alone, as well as no reports of consistent increase in vocal
intensity over the course of LSVT LOUDÒ therapy.53
Treatment effects of LSVT LOUDÒ has been mostly studied in the clinic and using various tasks such as sustained
phonation, reading, monologue. However, the monologue
measured in clinic has been brief ranging from 30 to 60 second samples. 35-37 Improvements reported in the conversational measures of speech intensity in clinic are
inconsistent across studies. For example, maintenance of
increased speech intensity for conversation at follow-up
was found in some studies 36,37,54 while other studies35,55
failed to ﬁnd evidence for improvements in speech intensity

for conversation at follow-up. An audit by Wight and
Miller (2015) replicated this ﬁnding. Their clients continued to have louder sustained vowel production two years
post LSVT LOUDÒ but did not maintain increased loudness in reading and monologue tasks during the 12 month
and 24-month follow up.56 In another single case study,
the IwPD increased conversational voice intensity in daily
life by 4.1 dB post- LSVT LOUDÒ treatment and 1.4 dB at
one-year follow-up compared to before treatment.38 While
this ﬁnding is promising, it cannot be generalized to the
PD population. More studies are needed to determine if
treatments such as LSVT LOUDÒ and/or biofeedback
improve carry over of conversational loudness from clinic
to real-life environments.
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TABLE 2.
Least Square Mean with Standard Errors of Vocal Intensity in Clinic and Real-life Environment at Baseline, End of Treatment and During One-month Follow-up
Variable (Environment)

Response

Baseline

Clinic
RLE
Clinic
RLE
Clinic
RLE
Clinic
RLE
Clinic
RLE
Clinic
RLE

Group 1 at end of treatment
Group 2 at end of treatment
Group 1 at follow up
Group 2 at follow up
All data combined

LS Mean (SE) of dB

P-Value

71.7 (1.5)
69.6 (0.8)
71.9 (3.3)
67.6 (1.0)
70.8 (1.5)
69.5 (1.7)
72.7 (3.0)
69.5 (1.7)
69.5 (1.5)
68.5 (0.9)
71.2 (1.6)
69.2 (0.5)

0.251
0.341
0.735
0.447
0.611
0.268

Group 1- LSVT LOUDÒ and VF; Group 2 - VF only
Abbreviation: RLE, Real life environment; VF, Vibrotactile feedback

In this study, VF did not result in improvement in vocal
intensity at the end of treatment and at follow-up. This ﬁnding is similar to another study where tactile biofeedback did
not improve vocal intensity in an IwPD.43 Although our
study ﬁndings are in contrast with Schalling et al, (2013)
which resulted in statistically signiﬁcant improvement in
vocal intensity with tactile biofeedback in IwPD, the
improvement was only 1.5 dB which has limited clinical signiﬁcance.23 Improvements in vocal intensity and generalization of treatment beneﬁts could be related to the frequency
and duration of biofeedback provided. This study was carried out for a total of 4 weeks to be consistent with the
LSVT LOUDÒ protocol while other studies have taken 1-3
TABLE 3.
Comparison of Conversational Vocal Intensity between
Treatment Groups in Real-life Environment at Baseline,
During Treatment and at Follow-up
Variable

Response

LS Mean
(SE) of dB

P-Value

Baseline only

Group 2
Group 1
Group 2
Group 1
Group 2
Group 1
Group 2
Group 1
Group 2
Group 1
Group 2
Group 1
Group 2
Group 1

71.1 (0.8)
68.8 (0.9)
71.2 (1.1)
67.5 (1.4)
71.6 (1.2)
69.6 (1.4)
70.3 (2.6)
63.9 (3.3)
69.0 (0.8)
67.9 (1.0)
70.5 (0.8)
67.2 (1.0)
68.5 (1.1)
69.5 (1.3)

0.134

Week 1 only
Week 2 only
Week 3 only
Week 4 only
Weeks 1-4 only
Follow up only

0.086

weeks. 23,43 VF was provided for a total of 8 days in this
study while other studies in the literature have provided
feedback for only for 3-5 days.23, 43 Also, the frequency of
feedback varied among these studies. 23,43 In future studies,
the frequency of vibration should be tailored to the individual, for example, some IwPD may need more feedback than
others. In this study, VF was provided when vocal intensity
dropped below the set threshold for 500ms. The delay was
set to 500ms based on the recommendation by Gustaffson
et al, (2016).43 Despite this, some IwPD in this study felt
that the VF was constant. The VL2 does not provide information on number of times the VF feature was activated.
To draw a comparison, in another study that used the
Ambulatory Phonation Monitor (APM) to provide tactile
biofeedback to improve vocal intensity in one IwPD, the
APM vibrated 377-1138 times on a single day.43 Such
increased frequency of feedback can make it challenging for

TABLE 4.
Comparison of Conversational Vocal Intensity between
Baseline and Follow-up for Both Treatment Groups in
Clinic and Real-life environments
Variable

Response

LS Mean
(SE) of dB

P-Value

Group 2

Baseline (RLE)
Follow-up (RLE)
Baseline (clinic)
Follow-up
(clinic)
Baseline (RLE)
Follow-up (RLE)
Baseline (clinic)
Follow-up
(clinic)

71.1 (0.8)
68.8 (0.9)
72.1 (2.5)
69.5 (2.3)

0.134

68.4 (1.3)
70.3 (1.3)
71.0 (3.0)
72.7 (3.0)

0.400

0.320
0.182
0.429
0.044*
0.582

* Statistically significant (P < 0.05) difference in vocal intensity between
groups 1 and 2
Group 1- LSVT LOUD and VF; Group 2 - VF only

Group 1

0.454

0.712

Group 1- LSVT LOUD and VF; Group 2 - VF only
Abbreviation: RLE, Real life environment; VF, Vibrotactile Feedback
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FIGURE 2. Average vocal intensity as measured by Vocalog2 in clinic and real-life environment (RLE) for each participant.

IwPD to facilitate motor learning of a new behavior. Future
technology should allow for individual control over when to
activate the VF as all situations may not require the use of a
loud voice. Also, tailoring the frequency and duration of
VF to the individual may be more meaningful. IwPD can
become dependent on sensory cues with constant feedback
and ﬁnd it hard to achieve automatization.47 The VL2 does
not measure environmental noise and hence the effect of
background noise on vocal intensity could not be determined in this study.
Methodological considerations and limitations: Results of
this study must be interpreted with caution due to the small
sample size and disproportionate number of participants in
each treatment group. In addition, all the participants in
Group 2 had MCI and those in Group 1 did not. Although,
prevalence of MCI is common in PD without dementia57,
the MCI could have inﬂuenced how the IwPD paid attention to the VF. Hypophonia was rated by the clinician on
the CAPE-V to be mild or mild-moderate in severity for all
participants except two of them. However, self-perception
of voice problem on the VHI was rated as “severe” by 5 participants, “moderate” by 2 participants and “normal” by
one participant. It is important to include IwPD with varying severity of hypophonia as the motivation and “room for
improvement” may vary in treatment. The average baseline
vocal intensity of our participants was 71.7 dB in clinic and
69.3 dB in real-life. This is close to the normal limit of about
70 dB for connected speech.58 These close to normal values
may have contributed to a lack of signiﬁcant difference in
the results in addition to the small sample size. The baseline
vocal intensity values in this study are consistent with
literature.23,36,37 Also, all study participants were referred to
the Speech Pathology clinic as they complained of hypophonia to the Neurologist.

Device-related limitations: All eight participants wore the
VL2 for four days at least each week as instructed. Some
participants wore the monitor for longer than four days on
certain weeks or longer than four hours on a given day since
they felt that they do not have to strictly monitor the hours.
In that case, data from the ﬁrst four days of each week and
ﬁrst four hours of each day were analyzed. Just like any
technology, the VL2 had its fair share of challenges. If technical malfunction occurred such as the device did not
vibrate or data was not registered, the registration period
was prolonged within each week. Although the monitor was
worn for four hours, the vocal activity varied for each subject and during each day within a subject. The VL2 monitor
picks up the voiced sounds and records it as vocal activity.
It is impossible to control the amount of vocal activity for
everyone. Another limitation is the design of the vocal monitor. The vocal monitor of the VL2 system is a neckband.
Although the neckband was adjustable and came in various
sizes and was ﬁtted to the IwPD, participants provided feedback that it did move at times and that they had to adjust it.
Also, the vibratory response of the monitor must be improvised since participants felt that it vibrated occasionally for
non-vocal sounds.
Communicative environment also could inﬂuence results
and needs to be further investigated. In the clinic environment, only two people were present (the clinician and the
IwPD). However, in real-life environments, the number of
communication partners present varies, the distance
between the communication partners varies, and as a result
the motivation of IwPD to speak louder may vary. Medication ON-OFF effects were also not monitored. We did not
control for these factors since the goal was to capture speaking in a natural environment over a period. These factors,
however, should be explored in further studies with larger
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sample sizes to further understand the effect of environment
on conversational demands in IwPD.

CONCLUSION
This study investigated the effects of hypophonia treatment
on conversational vocal intensity of IwPD in real-life environments and compared vocal intensity between the clinic
and real-life environment. While no signiﬁcant differences
in vocal intensity were discovered between the two environments and therapy approaches, the ﬁndings imply that clinicians use 20 minutes of dialogue in clinic to get a good
representation of patients’ vocal intensity in the real world.
With advancing technology, the nature of vibratory feedback on motor-learning of a new behavior such as speaking
loudly needs further investigation. Large scale studies
including a placebo device with a variety of wearable devices are needed to assess carry over of hypophonia treatment
to real-life and to determine the most appropriate device for
a patient. Monitoring the conversational vocal intensity of
IwPD in real-life environments is a growing area of interest
and further studies investigating a standard methodology
for functional speech assessment and monitoring treatment
progress are warranted.
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